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Key pointsGenetic testing is increasingly applied in---MRI‐negative and MRI‐positive--- focal epilepsy patients who are considered for epilepsy surgeryIn almost half of patients who underwent genetic testing, genetic testing was performed only after the patient was already accepted or rejected for surgeryOutcome of genetic testing assists selecting eligible patients for invasive intracranial monitoring and resective or palliative surgery

1. INTRODUCTION {#epi412366-sec-0006}
===============

Epilepsy is one of the most common neurological diseases globally, with a lifetime prevalence of 7.6 in 1000 people.[1](#epi412366-bib-0001){ref-type="ref"} Up to one‐third of patients develop pharmacoresistance, and many have significant comorbidities, such as developmental delay.[2](#epi412366-bib-0002){ref-type="ref"}, [3](#epi412366-bib-0003){ref-type="ref"}, [4](#epi412366-bib-0004){ref-type="ref"}

In patients with pharmacoresistant focal epilepsy originating from a structural abnormality, resective surgery represents the only potentially curative treatment option provided that the lesion can be accurately delineated and is located outside eloquent cortex. In many patients, especially those without a structural abnormality, extensive preoperative diagnostic work‐up is required, including invasive intracranial EEG‐monitoring in an increasing number of patients.[4](#epi412366-bib-0004){ref-type="ref"} Despite rapidly improving presurgical diagnostic modalities and increasing clinical experience, patient selection for surgical treatment is still suboptimal, with on average only 65%‐69% of patients achieving postoperative seizure freedom.[6](#epi412366-bib-0006){ref-type="ref"}, [7](#epi412366-bib-0007){ref-type="ref"} Therefore, new and reliable markers to properly differentiate between patients with operable and non‐operable epilepsy are warranted.

In the last decades, novel epilepsy genes have been increasingly identified in patients with generalized and focal epilepsy.[8](#epi412366-bib-0008){ref-type="ref"} The possibilities to comprehensively test epilepsy patients for a genetic etiology have expanded throughout the last years, with the advent of readily available next generation sequencing techniques (NGS).[9](#epi412366-bib-0009){ref-type="ref"} In particular whole exome sequencing (WES), through which the coding sequence of all genes in the human genome can be scanned for apparent disease‐causing sequence variation, accelerated the discovery of novel epilepsy genes in the past decade.[10](#epi412366-bib-0010){ref-type="ref"} The importance of genetic causes of structural focal epilepsies was first established by the observation that inherited or de novo mutations in genes involved in the mTOR pathway, can cause focal epilepsy.[11](#epi412366-bib-0011){ref-type="ref"} It stands without a doubt that the identification of a causative mutation could affect treatment as well as prognostic and genetic counselling (Reif et al, 2016).[12](#epi412366-bib-0012){ref-type="ref"} Moreover, recent literature shows that some of the epilepsy gene mutations may also be related to the effectiveness of epilepsy surgery in focal epilepsy patients (Stevelink et al, 2018).[13](#epi412366-bib-0013){ref-type="ref"} We therefore hypothesize that genetic testing can add valuable information to current preoperative patient assessment.

To gain more insight in the evolution of diagnostic genetic testing in epilepsy surgery evaluation, we studied the application and yield of genetic testing within a large consecutive cohort of epilepsy patients who were evaluated for epilepsy surgery in a tertiary referral center over the past decades. We assessed differences in outcome between important subgroups of evaluated patients, especially focussing on MRI‐negative *vs* MRI‐positive patients.

2. METHODS {#epi412366-sec-0007}
==========

2.1. Patient selection {#epi412366-sec-0008}
----------------------

Patients were identified within the database of the Dutch Collaborative Epilepsy Surgery Program group, coordinated in the UMC Utrecht. We included all children and adults who were consecutively evaluated for epilepsy surgery from January 1, 1990, to January 1, 2017. We reviewed medical records, discharge letters, and outpatient clinical summaries of all identified patients. Subjects who did not complete the presurgical program (ie, patient self‐withdrawal), and those in whom the UMC Utrecht was not the operating theater were excluded from this analysis. Moreover, we excluded patients if adequate medical information on presurgical assessment could not be retrieved from the medical files. We separately report patients with tuberous sclerosis complex (TSC) and multiple cavernoma (due to KRIT1 or other CCM mutations) in this cohort, because these concern specific groups of patients in whom the diagnosis is made on the basis of the pathognomonic imaging (MRI) findings in combination with clinical criteria. Genetic testing in patients with TSC and multiple cavernoma is mainly performed to confirm the diagnosis and to facilitate genetic counselling. In addition, an extensive body of research to evaluate the role of epilepsy surgery in TSC has already been described elsewhere,[14](#epi412366-bib-0014){ref-type="ref"}, [15](#epi412366-bib-0015){ref-type="ref"} and genetic testing is not likely to be related to surgical success.

If patients were evaluated multiple times, solely the most recent episode of preoperative assessment was included as time point of surgical decision‐making. In patients who underwent reoperation for failed epilepsy surgery, we only assessed data on follow‐up after the last surgery.

The medical ethics committee of the UMC Utrecht approved the study and concluded that no informed consent was required for this retrospective observational study on available data from routine clinical care.

2.2. Data collection {#epi412366-sec-0009}
--------------------

We collected information on the results of all structural and functional imaging and genetic diagnostic modalities that were utilized within the presurgical evaluation trajectory of included patients. Results of brain MRI as reported by dedicated epilepsy neuroradiologists and the multidisciplinary team discussions at the time of presurgical evaluation were recorded for each of the patients. Scans were not rereviewed for the purpose of this study. In patients who underwent genetic diagnostics, results of each separate genetic test were collected. We evaluated the results of all clinical genetic tests performed, regardless of whether the genetic results became available before, during or after the presurgical trajectory.

We classified the genetic tests into six categories according to the different technologies that were used: 1) karyotype analysis, 2) array techniques (eg, SNP‐array or array‐CGH), and sequencing techniques consisting of 3) individual gene analysis, 4) targeted gene panels (categorized into 10 panels; examples are as follows: focal epilepsy, fever‐sensitive epilepsy or epileptic encephalopathy), 5) full epilepsy gene panel (including \>130 epilepsy genes up to \>170 in recent years), and 6) whole exome sequencing (WES). All tests were performed on blood samples and reported causal variants concern germline mutations. Reported genetic variants and clinical information were reviewed by two authors: EB---an experienced clinical geneticist---and MS. Variants were classified into five categories (according to the American College of Medical Genetics and Genomics criteria) that convey information about the probability of representing a pathogenic variant that is causative for the patients' epilepsy.[16](#epi412366-bib-0016){ref-type="ref"} These categories comprised i) benign ii) likely benign iii) uncertain significance, iv) likely pathogenic, and v) pathogenic. For the analysis of this study, we considered solely class iv (likely pathogenic) and v (pathogenic) variants to be causative for the epilepsy. We assessed the pathogenic nature of variants with the use of common predictors for pathogenicity such as segregation analysis, functional analysis, appearance of the mutation in variant‐related control databases, and molecular features of the mutation itself.

If epilepsy surgery was performed, we extracted information on type of surgery, histopathological diagnosis, and postoperative seizure outcome from the patients' clinical files. Seizure outcomes at 1 year of follow‐up after surgery were classified according to the Engel classification system; we defined seizure freedom as complete cessation of seizures---including aura\'s---(Engel 1A).[17](#epi412366-bib-0017){ref-type="ref"}

3. RESULTS {#epi412366-sec-0010}
==========

Medical information was retrieved of 2385 people with epilepsy (1022 children; 43%) who completed the presurgical evaluation program within the UMC Utrecht (Figure [1](#epi412366-fig-0001){ref-type="fig"}). Of these, 450 (19%) had no reported MRI abnormalities causative for the epilepsy ("MRI‐negative"), whereas 1935 subjects (81%) were classified as "MRI‐positive", with a lesion considered epileptogenic. Complete postoperative seizure freedom (Engel 1A) in all operated patients (n = 1280) occurred significantly more often in MRI‐positive patients (74%) compared with the MRI‐negative patients (49%, *P* = \<0.001).

![Enrolment of study patients](EPI4-4-0-g001){#epi412366-fig-0001}

In total, 662 genetic tests were performed in 325 of all patients (14%). MRI‐negative patients were significantly more likely to undergo genetic testing than patients who had a causative MRI‐lesion (35% vs 9%, OR 3.9; 95% CI 3.2‐4.7). Outcome of surgical evaluation with respect to different subgroups of patients is listed in Table [1](#epi412366-tbl-0001){ref-type="table"}. Overall, 181 of 325 patients (56%) underwent genetic testing with results available before completion of the presurgical evaluation trajectory, whereas in the remaining 44% genetic testing was performed only after the patient was already accepted or rejected for surgery. Fifteen of the 40 subjects (38%) in whom a genetic diagnosis could be established underwent genetic analysis only after surgical decision‐making.

###### 

Outcome of surgical evaluation with respect to different subgroups of patients

  I: Cohort                                                   II: Surgical decision   III: Surgical outcome   
  ----------------------------------------------------------- ----------------------- ----------------------- -------------------------------------------------------
  All patients                                                2385                    1280 (54)               863/1209[a](#epi412366-note-0001){ref-type="fn"} (71)
  MRI‐negative                                                450                     119 (26)                52/106 (49)
  MRI‐positive                                                1935                    1161 (60)               811/1103 (74)
  Genetic testing                                             325                     113 (35)                49 (43)
  MRI‐negative                                                156                     34 (22)                 9 (26)
  MRI‐positive                                                169                     79 (47)                 40 (51)
  Genetic diagnosis                                           40                      13 (30)                 5 (38)
  MRI‐negative                                                25                      2 (8)                   1 (50)
  MRI‐positive                                                15                      9 (60)                  3 (33)
  mTOR gene mutations                                         7                       3 (42)                  2 (67)
  Channel function and synaptic transmission gene mutations   17                      1 (6)                   0 (0)

Exact data on surgery outcome could not be retrieved in 74 of 1283 cases.
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The annual number of patients evaluated for epilepsy surgery gradually increased from 33 (8 MRI‐negative and 25 MRI‐positive) in 1990 to 188 (42 MRI‐negative and 146 MRI‐positive) in 2016 (Figure [2](#epi412366-fig-0002){ref-type="fig"}A,B). The percentage of patients undergoing genetic testing increased from 3% in 1991 to an average of 30% of all evaluated patients in the past 5 years. In 1991, 13% of MRI‐negative patients *vs* 0% of the MRI‐positive group underwent genetic testing, and over the past 5 years, genetic testing was performed in 69% of MRI‐negative patients *vs* 20% of the MRI‐positive population. Genetic testing performed between 1990 and 2013 resulted in 13 of the 43 (30%) genetic diagnoses, whereas the remaining 30 (70%) genetic causes were established from 2013 onwards.

![A‐D, Annual (1990‐2016) number of patients who underwent (i) presurgical assessment (unbroken line) and (ii) genetic testing (broken line; A, B) and quantity and type of genetic tests performed (C, D). Red color: MRI‐positive patients; blue color: MRI‐negative patients](EPI4-4-0-g002){#epi412366-fig-0002}

Karyotyping and array techniques were among the most commonly used types of genetic testing from 1990 to 2010, whereas from 2005 onwards, NGS techniques were also used more widely (Figure [2](#epi412366-fig-0002){ref-type="fig"}C,D). Together with full epilepsy gene panels and WES, which were first used within this cohort in 2013 and 2014, respectively, these multiple gene sequencing techniques are currently the most widely used and efficient techniques for mutation screening in patients evaluated for epilepsy surgery.

Genetic testing yielded an abnormal finding (ie, genetic variant) in 144 of all patients (44%) tested, comprising 77 of 156 MRI‐negative patients (49%) *vs* 67 of 169 MRI‐positive (40%) patients. A (likely) pathogenic variant was found in 40 of the 325 tested patients and did not significantly differ between MRI‐negative and MRI‐positive patients (20 vs 20 patients, respectively, *P* = .404). As expected, the diagnostic yield of multiple gene sequencing (NGS) techniques was significantly higher (*P* =\< .001) compared with other tests. The diagnostic yield with respect to finding disease‐causing variants was lowest for array techniques (2%) and individual gene analysis (2%) and highest for full epilepsy panel sequencing (17%) and whole exome sequencing (24%). The diagnostic yield of different types of genetic testing is listed in Table [2](#epi412366-tbl-0002){ref-type="table"}.

###### 

Outcome (III) and diagnostic yield (disease‐causing variants) of genetic testing with regard to type (I) and number (II) of genetic tests performed

  I: Type of testing                                                  II: Frequency of testing   III: Findings   
  ------------------------------------------------------------------- -------------------------- --------------- ---------
  Karyotype analysis                                                  91                         3 (3)           3 (3)
  Array technique                                                     165                        47 (28)         4 (2)
  Individual gene sequencing                                          56                         4 (7)           1 (2)
  Targeted panel sequencing[a](#epi412366-note-0002){ref-type="fn"}   257                        39 (15)         14 (5)
  Febrile related epilepsy                                            91                         19 (21)         6 (7)
  Focal epilepsy                                                      42                         8 (19)          3 (7)
  Epileptic encephalopathy                                            49                         7 (14)          3 (6)
  Progressive myoclonic epilepsy                                      10                         1 (10)          1 (10)
  Benign neonatal convulsions                                         21                         1 (5)           0 (0)
  Epilepsy and mental retardation                                     37                         3 (8)           2 (5)
  Idiopathic generalized epilepsy                                     3                          0 (0)           0 (0)
  Paroxysmal disorders                                                3                          0 (0)           0 (0)
  Inflammation mediated epilepsy                                      1                          0 (0)           0 (0)
  Full epilepsy panel sequencing                                      64                         34 (53)         11 (17)
  Whole exome sequencing                                              29                         17 (58)         7 (24)
  Total                                                               662                        144 (22)        40 (6)

Panels as listed below included a number of genes that varied over time; more recent panels contained more genes. Furthermore, some genes were included in several panels.

John Wiley & Sons, Ltd

3.1. Outcome in patients with an established genetic diagnosis {#epi412366-sec-0011}
--------------------------------------------------------------

Three of the seven patients with mTOR pathway gene mutations (2 *DEPDC5*; 1 *NPRL3*) underwent surgery (Tables [3](#epi412366-tbl-0003){ref-type="table"} and [S1](#epi412366-sup-0001){ref-type="supplementary-material"}). Two of these (one MRI‐negative) achieved complete seizure freedom. The third (MRI‐negative) operated patient was not rendered seizure‐free after surgery; the surgical report noted a tailored, possibly incomplete, resection of the epileptogenic zone in an eloquent (left precentral) area. Histopathological examination of the resected tissue in this patient was not indicative for a focal cortical dysplasia (FCD, nor did it reveal any other abnormalities. Three of the four patients with mTOR pathway gene mutations who were rejected for surgery were MRI‐negative, and in 2 of these 4 (1 MRI‐negative and 1 MRI‐positive), the genetic diagnosis was established only after rejection for surgery.

###### 

Timing of genetic analysis (pre‐ vs postsurgical decision‐making) and surgical outcome (seizure freedom) in patients with a pathogenic variant

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Neurobiological pathway                                        Pathogenic variant (N)\   Genetic testing                                   
                                                                 N = 40 (total)                                                              
  -------------------------------------------------------------- ------------------------- ----------------- ------- --- --- ------- --- --- ---
  mTOR pathway (n = 7, 18%)                                      *DEPDC5 (5)*              1 (0)             ‐       ‐   2   1 (1)   ‐   ‐   1

  *NPRL3 (2)*                                                    ‐                         1 (1)             ‐       ‐   ‐   ‐       ‐   1   

  Ion channel function and synaptic transmission (n = 17, 43%)   *SCN1A (6)*               ‐                 ‐       ‐   3   ‐       ‐   2   1

  *KCNT1 (3)*                                                    ‐                         ‐                 ‐       ‐   ‐   ‐       ‐   3   

  *GRIN2A (2)*                                                   ‐                         ‐                 ‐       1   ‐   ‐       ‐   1   

  *STXBP1 (2)*                                                   ‐                         ‐                 ‐       ‐   ‐   ‐       ‐   2   

  *SLC35A2 (1)*                                                  ‐                         ‐                 ‐       1   ‐   ‐       ‐   ‐   

  *CHRNA4 (1)*                                                   ‐                         ‐                 ‐       1   ‐   ‐       ‐   ‐   

  *GABRA3 (1)*                                                   ‐                         ‐                 ‐       ‐   ‐   ‐       ‐   1   

  *CNTNAP2 (1)*                                                  ‐                         1 (0)             ‐       ‐   ‐   ‐       ‐   ‐   

  Cell‐cell adhesion (n = 1, 2%)                                 *PCDH19 (1)*              ‐                 ‐       ‐   ‐   ‐       ‐   ‐   1

  Protein translation and modification (n = 2, 5%)               *PNKP (1)*                ‐                 ‐       ‐   1   ‐       ‐   ‐   ‐

  *QARS (1)*                                                     ‐                         ‐                 ‐       1   ‐   ‐       ‐   ‐   

  Neuronal migration, neurogenesis (n = 1, 2%)                   *ARX (1)*                 ‐                 1 (1)   ‐   ‐   ‐       ‐   ‐   ‐

  Other causes (n = 12, 30%)                                     *Microdeletions (4)*      ‐                 2 (0)   ‐   1   ‐       ‐   ‐   1

  *Ring 20 (3)*                                                  ‐                         ‐                 ‐       2   ‐   ‐       ‐   1   

  *NF1 (2)*                                                      ‐                         2 (1)             ‐       ‐   ‐   ‐       ‐   ‐   

  *ANKRD11 (1)*                                                  ‐                         1 (1)             ‐       ‐   ‐   ‐       ‐   ‐   

  *NBEA (1)*                                                     ‐                         ‐                 ‐       ‐   ‐   ‐       ‐   1   

  *WDR26 (1)*                                                    ‐                         ‐                 ‐       ‐   ‐   1 (0)   ‐   ‐   
  ----------------------------------------------------------------------------------------------------------------------------------------------

John Wiley & Sons, Ltd

Of the 17 patients (12 being MRI‐negative) with germline mutations in ion channel function and synaptic transmission genes, only one (*CNTNAP2*) was accepted for epilepsy surgery. It concerned a patient in whom the genetic diagnosis was established preoperatively, with a subtle right temporal MRI‐lesion that was consistent with the patient\'s semiology and ictal EEG findings. The patient underwent a focal resection and histopathological examination of resected tissue showed gliosis and was not indicative for any specific abnormalities. Five months after surgery the seizures recurred. Two other patients had undergone intracranial EEG‐monitoring and were rejected for resective surgery. In both, genetic results became available only months after the presurgical evaluation was completed. Overall, in 10 of the 17 patients (59%) with germline mutations in ion channel function and synaptic transmission, the genetic etiology was established only after rejection for surgery.

Seven of the 13 patients with epilepsy due to genetic causes other than mTOR pathway gene mutations or mutations in ion channel function and synaptic transmission genes received surgery. This group comprised two patients with a *NF1* pathogenic variant; one patient with epilepsy due to a 1q44 deletion (MRI‐showed unilateral polymicrogyria); one patient with a 12p13.33 deletion (MRI and histopathological examination indicative for hippocampal sclerosis); one patient with an *ARX* mutation (MRI‐showed unilateral polymicrogyria); one patient with an *ANKRD11* pathogenic variant (KBG‐syndrome, MRI suggestive for FCD whereas histopathological examination was unremarkable); and one patient with a *WDR26* pathogenic variant (MRI showed hemiatrophy). Complete seizure cessation was achieved in 3 of these 10 patients. All three patients with ring chromosome 20 were rejected for surgery.

3.2. Patients with tuberous sclerosis complex and KRIT1 mutations {#epi412366-sec-0012}
-----------------------------------------------------------------

There were 53 patients evaluated for surgery in whom a clinic‐radiological diagnosis of TSC was established. Individual gene analysis in these patients resulted in a genetic diagnosis (*TSC1* or *TSC2* mutation) in 45 patients. In all but two patients, the genetic diagnosis was already known before the patients entered the epilepsy surgery evaluation program.

Three patients were found with epilepsy due to cavernomas in the context of a *KRIT1* pathogenic variant. Two of these patients were seizure‐free (Engel 1A) one year after surgery.

4. DISCUSSION {#epi412366-sec-0013}
=============

In the past decades, there is a distinct increase in the application of genetic testing among patients with pharmacoresistant epilepsy who entered the Dutch comprehensive presurgical evaluation program, particularly in those with normal MRI. Furthermore, the spectrum of genetic technologies embedded in the presurgical assessment expanded clearly over the last 10 years, with a shift toward NGS technology. These two findings are parallel and were expected due to the rapid developments in the field of genetic technologies that improved clinically available and cost‐effective genetic testing in epilepsy patients. The accelerated discovery of genes in human epilepsy together with the advent of readily available multiple gene sequencing techniques resulted in a significantly increased detection of disease‐causing variants in our cohort. Our findings highlight the need for genetic testing in focal epilepsy in general and its potential use in epilepsy surgery evaluation specifically.

For the purpose of this study and to maintain a "real life situation," results of brain imaging as reported by experienced clinical neuroradiologists at the time of evaluation were not rereviewed. It is commonly accepted that having a causative focal or unilateral structural abnormality on MRI (MRI‐positive) is a strong predictor of good surgical outcome.[18](#epi412366-bib-0018){ref-type="ref"} This finding was confirmed in our study, with 74% seizure freedom in MRI‐positive compared with 49% in MRI‐negative patients. This emphasises the need for improved imaging or post‐processing methods, and for new, non‐invasive diagnostic modalities that could improve presurgical decision‐making and ultimately surgical success.

In this study, 2 of 3 operated patients with mTOR pathway gene mutations achieved seizure freedom (one of whom being MRI‐negative) after surgery. These findings are in accordance with the results of our recent literature review, which showed that surgery in FE patients with mTOR pathway gene mutations---likely representing a focal, structural cause for epilepsy---had a relatively higher success rate compared with other genetic causes.[13](#epi412366-bib-0013){ref-type="ref"} The characteristics of the MRI‐negative third patient with no postoperative reduction of seizure frequency (small resection in an eloquent area and no pathology identified in resected tissue), point toward the possibility of an incomplete resection of the epileptogenic focus; the patient is therefore currently being reevaluated. These three epilepsy patients are representative for the population in which a genetically established diagnosis can point toward an "MRI‐invisible" microstructural lesion or malformation of cortical development, probably implying a reasonable chance of postoperative seizure freedom. Genetic testing could help to differentiate between this category of patients and those with a genetic syndrome that is not accompanied with an identifiable lesion---probably reflecting a lower chance of surgical success---, or by a combination of the two.

On the other hand, genetic testing could also improve decision‐making in MRI‐positive patients. The identification of an mTOR gene mutation early in the presurgical evaluation could, together with other presurgical diagnostic modalities, add strength to the congruence of a structural localized epileptogenic focus.

The finding of a pathogenic variant indicating a genetic syndrome without a structural cause of epilepsy suggests poor surgical candidacy and outcome. Of the 14 patients reported in the literature with a mutation in genes related to ion channel or synaptic function, only 2 patients (14%) became seizure‐free after surgery.[13](#epi412366-bib-0013){ref-type="ref"} Of our 17 patients with such mutations, 16 patients were rejected because presurgical assessment failed to localize the epileptogenic zone. One MRI‐positive patient (*CNTNAP2* mutation) received surgery and was not rendered seizure‐free; clinical history and surgical outcome of this patient were in accordance with the few previously reported in the literature.[19](#epi412366-bib-0019){ref-type="ref"} Two patients were rejected after they underwent invasive monitoring. In these two patients, a *SCN1A* mutation was only found after the invasive monitoring had been performed. These findings suggest that identification of a pathogenic variant in this group of genes (before or during the presurgical evaluation) could prevent unnecessary extensive and expensive presurgical evaluation, and especially resective surgery or invasive source localization techniques in MRI‐negative and MRI‐positive patients with an epilepsy phenotype not fully in concordance with the lesion. In the latter group, however, surgery may be considered to only target lesion related seizures in patients with dual pathology (eg, patients with SCN1A mutations and hippocampal sclerosis).

In conclusion, there is a clear increase in the use of genetic testing in patients evaluated for epilepsy surgery, which can be explained by a rapid evolution of genetic techniques, the extensive discovery of novel generalized as well as focal epilepsy genes in the last decade, and the increase in number of MRI‐negative patients, in whom both structural and non‐structural genetic etiologies are increasingly considered in the differential diagnosis.

However, genetic diagnostics are still not routinely performed before deciding to operate patients or reject them from surgery or from invasive monitoring. In many proposed flow diagrams of presurgical evaluation, genetic testing is not listed, and in the recent ILAE evaluation of presurgical test utility, genetic tests were not included.[20](#epi412366-bib-0020){ref-type="ref"}, [21](#epi412366-bib-0021){ref-type="ref"} Moreover, in almost half of the patients who underwent genetic testing, the genetic diagnosis was established only after the patient was already accepted or rejected for surgery.

The low number of surgical cases for most genetic causes and the heterogeneity of pathogenic variants leave open questions. Therefore, a prospective study is warranted to identify causative epilepsy gene variants in patients who are evaluated for surgery, that can either point toward structural focal and presumably surgically remedial causes of epilepsy, or toward primary genetic non‐lesional causes of epilepsy. We are currently undertaking this study with the hypothesis that genetic testing in patients with pharmacoresistant epilepsy can improve differentiation between good surgical candidates, and those who are less eligible for epilepsy surgery.
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